Opus Genetics, Inc. (IRD): Total Assets
$50.24M
As of 2025-12-31
$92.97M
As of 2026-06-30
+0.8%
3-year compound annual growth
+23.2%
5-year compound annual growth
+7.3%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $50.24M | +36.3% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $36.86M | -31.7% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $53.95M | +10.1% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $48.99M | +87.9% | 2024-03-08, Balance as of period end |
| 2021-12-31 | $26.08M | +47.5% | 2023-03-30, Balance as of period end |
| 2020-12-31 | $17.68M | +891.1% | 2022-03-24, Balance as of period end |
| 2019-12-31 | $1.78M | -88.9% | 2021-03-11, Balance as of period end |
| 2018-12-31 | $16.04M | -43.3% | 2020-02-21, Balance as of period end |
| 2017-12-31 | $28.29M | +34.4% | 2019-03-07, Balance as of period end |
| 2016-12-31 | $21.04M | -15.2% | 2018-03-09, Balance as of period end |
| 2015-12-31 | $24.81M | -26.0% | 2017-02-24, Balance as of period end |
| 2014-12-31 | $33.53M | +71.5% | 2016-03-14, Balance as of period end |
| 2013-12-31 | $19.56M | +31.1% | 2015-03-16, Balance as of period end |
| 2012-12-31 | $14.92M | +9.0% | 2014-03-21, Balance as of period end |
| 2011-12-31 | $13.69M | -15.6% | 2013-03-22, Balance as of period end |
| 2010-12-31 | $16.22M | n/a | 2012-03-16, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | 2025-12-31 | $50.24M | +36.3% |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | $94.62M | -28.2% |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $91.52M | -41.8% |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $6.96M | -12.2% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $277.17M | +70.2% |
| Evommune, Inc. (EVMN) | 2025-12-31 | $224.95M | +195.8% |
| uniQure N.V. (QURE) | 2025-12-31 | $824.91M | +48.2% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $21.44M | -9.2% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $141.31M | -19.5% |
Compare IRD, ABUS, PYXS, CVSI side by side · Screen every company in Pharmaceutical Preparations ↗